Drug and Chemical Toxicology is a well-respected journal in the fields of toxicology, pharmacology, and public health, published by Taylor & Francis Ltd. Since its inception in 1978, this journal has diligently explored the effects and mechanisms of chemical exposures on health and the environment, fulfilling a crucial role in advancing scientific understanding and safeguarding public health. The journal is indexed across prestigious databases and features an impressive array of articles categorized within the Q2 and Q3 quartiles across various categories in 2023, reflecting its significance in Chemical Health and Safety as well as Environmental and Occupational Health disciplines. With an extensive reach and a focus on interdisciplinary research, Drug and Chemical Toxicology offers a rich repository of original research, reviews, and methodological advancements, catering to a diverse audience of researchers, professionals, and students dedicated to the betterment of safety and health standards. Although not an open-access publication, its articles are widely accessible to the academic community, ensuring that critical innovations and insights are shared for the greater good.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

Genes and Nutrition is a prominent open access journal published by BMC in the United Kingdom, dedicated to advancing knowledge at the intersection of nutrition, genetics, and human health. With the aim of making cutting-edge research available to a global audience, the journal has been a vital platform for sharing discoveries since its inception in 2007, and it continues to thrive with a convergence period extending to 2024. Recognized for its high-quality contributions, Genes and Nutrition is rated in the Q2 category within both Endocrinology, Diabetes, and Metabolism and Genetics as of 2023, reflecting its esteemed position in these fields (Scopus Ranks leaderboard places it at #72/244 and #109/347, respectively). This journal is an invaluable resource for researchers, professionals, and students alike, fostering collaboration and innovation in the understanding of how genetic factors influence nutrition and health outcomes. Accessible to all since 2016, it encourages dialogue and discovery, positioning itself as a leader in genetic and nutritional science.

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, published by Elsevier, stands as a premier journal in the fields of Genetics and Health, Toxicology and Mutagenesis, boasting a Q1 ranking in both categories for 2023. With an impressive impact factor and rigorous peer-review process, this journal serves as a vital platform for disseminating cutting-edge research and comprehensive reviews regarding the implications of genetic mutations and related health effects. Established in the Netherlands, it has evolved from its inception in the early 1990s to become an essential resource for researchers, professionals, and students alike, facilitating advancements in the understanding of mutation research. Despite not offering an open-access model, the journal ensures a wide reach through institutional subscriptions, emphasizing its commitment to fostering scholarly dialogue and promoting significant findings within the scientific community.

Human Gene is an innovative open access journal published by ELSEVIER, dedicated to the ever-evolving field of genetics. Established in 2022, this journal serves as a vital resource for researchers, professionals, and students alike, aiming to facilitate the dissemination of groundbreaking research and advancements in both basic and clinical genetics. With an ISSN of 2773-0441, Human Gene focuses on providing a platform for high-quality studies that investigate genetic mechanisms, their implications in health and disease, and novel therapeutic strategies. The journal currently holds a Q4 ranking in both Genetics and Clinical Genetics categories, reflecting its emerging status within the scientific community, and strives to enhance its impact to better serve an engaged audience. With its base in Amsterdam, Netherlands, Human Gene is committed to making research accessible through its open access model, inviting contributions that advance our understanding of human genetics and foster collaboration across disciplines.

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

GENETICS AND MOLECULAR BIOLOGY, published by the SOC BRASIL GENETICA, is a prominent journal dedicated to the advancement of knowledge in the fields of genetics and molecular biology. Since its inception in 1998, this Open Access journal has served as a vital platform for researchers, professionals, and students to disseminate their findings and engage with the latest innovations and discoveries. With an impact factor that reflects its growing influence, GENETICS AND MOLECULAR BIOLOGY ranks in the Q3 category for both genetics and molecular biology as of 2023, indicating its position within the academic community. The journal is indexed in Scopus, highlighting its commitment to maintaining rigorous peer-review standards while providing wide-reaching access to quality research. Operating out of Ribeirão Preto, Brazil, it fosters a collaborative environment for academic discourse and research development not only in Brazil but also globally. The journal encourages submissions that explore a wide range of topics in genetics and molecular biology, making it an essential resource for anyone involved in these dynamic fields.

Environmental Epigenetics, published by Oxford University Press, is a leading open access journal dedicated to advancing the understanding of the epigenetic mechanisms that underpin environmental influences on health and disease. With an ISSN of 2058-5888 and established as an open access platform since 2015, this journal serves as a vital resource for researchers in the fields of genetics, environmental science, and health, offering insights from multidisciplinary perspectives. The journal has gained notable recognition in the academic community, reflected by its impressive Scopus rankings and its classification in the second quartile (Q2) for Genetics and other related disciplines as of 2023. It aims to foster innovative research that bridges laboratory findings and real-world environmental issues, making it an indispensable tool for professionals and students pursuing knowledge at the intersection of genetics, environmental science, and public health. With its commitment to disseminating valuable research findings freely, Environmental Epigenetics stands out as an essential publication for those aiming to understand the significant impacts of environmental factors on genetic expression.

Journal of Biochemical and Molecular Toxicology, published by Wiley, plays a pivotal role in the advancement of knowledge within the fields of biochemistry, toxicology, and molecular biology. Established in 1998, this esteemed journal has garnered a significant reputation, evidenced by its current placement in the Q2 quartile across several categories, including Biochemistry, Health, Toxicology and Mutagenesis, and Medicine. With an ISSN of 1095-6670 and an E-ISSN of 1099-0461, it serves an international audience, offering critical insights and innovative research that shape our understanding of biochemical interactions and toxicological assessments. While it does not operate on an open-access model, the journal ensures rigorous peer review and high-quality publication standards, making it a valuable resource for researchers, professionals, and students dedicated to the exploration of molecular toxicology. The journal's recognized impact within the scientific community is reflected in its competitive rankings among specialized journals, fostering significant contributions to both academic and applied contexts.

Epigenetics, published by Taylor & Francis Inc, is a leading journal in the fields of Cancer Research, Medicine (miscellaneous), and Molecular Biology. With an ISSN of 1559-2294 and an E-ISSN of 1559-2308, this journal has been paving the way for groundbreaking research since its inception in 2006, and it continues to play a crucial role in advancing our understanding of epigenetic mechanisms and their implications in health and disease. The journal is highly regarded, ranking in the Q1 category for Medicine and Q2 for both Cancer Research and Molecular Biology according to the 2023 category quartiles. Researchers and professionals in the field will find invaluable insights and innovative studies within its pages, making it an essential resource for those engaged in cutting-edge research. Although the journal is not open access, it encourages a comprehensive understanding through high-quality peer-reviewed content. With its creative exploration of the epigenetic landscape, Epigenetics serves as a vital platform for the sharing of knowledge that could lead to breakthroughs in treatments and therapies.